Third Harmonic Bio, Inc. (THRD)
After hours:
| Previous close | 13.65 |
| Open | 13.54 |
| Bid | 13.20 x 100 |
| Ask | 13.54 x 100 |
| Day's range | 13.00 - 13.61 |
| 52-week range | 4.70 - 16.94 |
| Volume | |
| Avg. volume | 150,020 |
| Market cap | 545.038M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.75 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.50 |
- GlobeNewswire
Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 7:30 a.m. ET. A live audio webcast will be available within the Investors & M
- GlobeNewswire
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H’25 Strengthened leadership team with the appointment of Christopher J. Dinsmore, Ph.D., to Chief Scientific Officer, Dennis Dean, Ph.D., to Chief Non-Clinical Development Officer, and the promotion of Jennifer Dittman to Chief Development Operations Officer Strong financial position with cash and cash equivalents totaling $262.8
ZacksAbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal
AbbVie (ABBV) inks an option-to-license and collaboration deal with Gilgamesh to develop next-generation therapies for psychiatric disorders.
